Molecular pathogenesis of oral submucous fibrosis - A collagen metabolic disorder

Journal of Oral Pathology and Medicine

Volumn 34, Issue 6, 2005, Pages 321-328

  Rajalalitha, P ^a   Vali, S ^a  

^a Institute of Bioinformatics   (India)

Author keywords

Collagen; Lysyl oxidase; Oral submucous fibrosis; Signaling pathway; Transforming growth factor beta

Indexed keywords

ALPHA INTERFERON; COLLAGEN; CYTOKINE; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN N PROTEINASE; PROTEIN LYSINE 6 OXIDASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

COLLAGEN METABOLISM; EXTRACELLULAR MATRIX; FIBROSIS; HISTOPATHOLOGY; HUMAN; MOUTH CAVITY; MOUTH DISEASE; PLASMINOGEN ACTIVATION; PRECANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ARECA; COLLAGEN; COLLAGEN DISEASES; HUMANS; ORAL SUBMUCOUS FIBROSIS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 20944432774     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2005.00325.x     Document Type: Review

References (66)

1. Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 1966; 22: 764-79.
2. Pindborg JJ, Murti PR, Bhonsle RB, Gupta PC, Daftary DK, Mehta FS. Oral submucous fibrosis as a precancerous condition. Scand J Dent Res 1984; 92: 224-9.
3. CannifF JP, Harvey W, Harris M. Oral submucous fibrosis: its pathogenesis and management. Br Dent J 1986; 160: 429-34.
4. van Wyk CW, Seedat HA, Phillips VM. Collagen in submucous fibrosis: an electron-microscopic study. J Oral Pathol Med 1990; 19: 182-7.
5. Kwan HW. A statistical study on oral carcinomas in Taiwan with emphasis on the relationship with betel nut chewing: a preliminary report. J Formas Med Assoc 1976; 75: 497-505.
6. Sinor PN, Gupta PC, Murti PR, et al. A case-control study of oral submucous fibrosis with special reference to the etiologic role of areca nut. J Oral Pathol Med 1990; 19: 94-8.
7. Canniff JP, Harvey W. The aetiology of oral submucous fibrosis: the stimulation of collagen synthesis by extracts of areca nut. Int J Oral Surg 1981; 10: 163-7.
8. Jeng JH, Ho YS, Chan CP, et al. Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes. Carcinogenesis 2000; 21: 1365-70.
9. Tsai CH, Chou MY, Chang YC. The up-regulation of cyclooxygenase-2 expression in human buccal mucosal fibroblasts by arecoline: a possible role in the pathogenesis of oral sub mucous fibrosis. J Oral Pathol Med 2003; 32: 146-53.
10. Haque MF, Meghji S, Khitab U, Harris M. Oral submucous fibrosis patients have altered levels of cytokine production. J Oral Pathol Med 2000; 29: 123-8.
11. Seedat HA, van Wyk CW. Betel-nut chewing and submucous fibrosis in Durban. S Afr Med J 1998; 74: 568-71.
12. Cox SC, Walker DM. Oral submucous fibrosis: A review. Aust Dent J 1996; 41: 294-9.
13. Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ. Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prev 2002; 11: 646-53.
14. Zain RB, Ikeda N, Razak IA, et al. A national epidemiological survey of oral mucosal lesions in Malaysia. Community Dent Oral Epidemiol 1997; 25: 377-83.
15. Murti PR, Bhonsle RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol 1985; 13: 340-41.
16. Chiba I. Prevention of BQ Chewers' Oral Cancer in the Asian-Pacific Area Asian Pacific. J Cancer Prev 2001; 2: 263-9.
17. Hardie J. Oral submucous fibrosis: a review with case reports. J Can Dent Assoc 1987; 53: 389-93.
18. Harvey W, Scutt A, Meghji S, Canniff JP. Stimulation of human buccal mucosa fibroblasts in vitro by betel-nut alkaloids. Arch Oral Biol 1986; 31: 45-9.
19. Shieh TY, Yang JF. Collagenase activity in oral submucous fibrosis. Proc Natl Sci Counc Republic China Part B Life Sci 1992; 16: 106-10.
20. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286-92.
21. Ghahary A, Shen YJ, Scott PG, Gong Y, Tredget EE. Enhanced expression of mRNA for transforming growth factor-β, type I and type III procollagen in human post-burn hypertrophic scar tissues. J Lab Clin Med 1993; 122: 465-73.
22. Zain RB, Ikeda N, Gupta PC, et al. Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, 1996. J Oral Pathol Med 1999; 28: 1-4.
23. IARC Anonymous. Tobacco habits other than smoking; betel-quid and areca-nut chewing; and some related nitrosamines. IARC Monogr Eval Carcinog Risk Chem Hum 1985; 37: 141-200.
24. Hoffmann D, Brunnemann KD, Prokopczyk B, Djordjevic MV. Tobacco-specific N-nitrosamines and areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans. J Toxicol Env Health 1994; 41: 1-52.
25. Chiang CP, Hsieh RP, Chen TH, et al. High incidence of autoantibodies in Taiwanese patients with oral submucous fibrosis. J Oral Pathol Med 2002; 31: 402-9.
26. Hogaboam CM, Steinhauser ML, Chensue SW, Kunkel SI. Novel roles for chemokines and fibroblasts in interstitial fibrosis. Kidney Int 1998; 54: 2152-9.
27. Kupper TS. Immune and inflammatory processes in cutaneous tissues, Mechanisms and speculation. J Clin Invest 1990; 86: 1783-9.
28. ElAttar TMA. Cancer and the prostaglandins: a mini review on cancer research. J Oral Pathol 1985; 14: 511-22.
29. Gao Y, Ling T, Wu H. Expression of transforming growth factor beta 1 in keratinocytes of oral submucous fibrosis tissue. Zhonghua Kou Qiang Yi Xue Za Zhi (Chinese) 1997; 32: 239-41 (Abstract).
30. Rajendran R, Vijayakumar T, Vasudevan DM. An alternative pathogenetic pathway for oral submucous fibrosis (OSMF). MED Hypotheses 1989; 30: 35-7.
31. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-β/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001; 276: 17058-62.
32. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-β: Involvement of Smad 3. J Invest Dermatol 1999; 112: 49-57.
33. Vindevoghel L, Kon A, Lechleider RJ, Uitto J, Roberts AB, Mauviel A. Smad-dependent transcriptional activation of human type VII collagen gene (COL7A1) promoter by transforming growth factor-β. J Biol Chem 1998; 273: 13053-7.
34. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995; 64: 403-34.
35. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS. Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science 1996; 271: 360-362.
36. Kessler E, Adar R. Type I procollagen C-proteinase from mouse fibroblasts. Purification and demonstration of a 55-kDa enhancer glycoprotein. Eur J Biochem 1989; 186: 115-121.
37. Lee S, Solow-Cordero DE, Kessler E, Takahara K, Greenspan DS. Transforming growth factor-beta regulation of bone morphogenetic protein-1/procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes. J Biol Chem 1997; 272: 19059-66.
38. Lapière CM, Lenaers A, Kohn LD. Procollagen peptidase: an enzyme excising the coordination peptides of procollagen. Proc Natl Acad Sci USA 1971; 68: 3054-8.
39. Hojima Y, McKenzie J, van der Rest M, Prockop DJ. Type I procollagen N-proteinase from chick embryo tendons. Purification of a new 500-kDa form of the enzyme and identification of the catalytically active polypeptides. J Biol Chem 1989; 264: 11336-45.
40. Nusgens BV, Goebels Y, Shinkai H, Lapiere CM. Procollagen type III N-terminal endopeptidase in fibroblast culture. Biochem J 1980; 191: 699-706.
41. Rucker RB, Romero-Chapman N, Wong T, et al. Modulation of lysyl oxidase by dietary copper in rats. J Nutr 1996; 126: 51-60.
42. Panchenko MV, Stetler-Stevenson WG, Trubetskoy OV, Gacheru SN, Kagan HM. Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. J Biol Chem 1996; 271: 7113-9.
43. Kosonen T, Uriu-Hare JY, Clegg MS, Keen CL, Rucker RB. Incorporation of copper into lysyl oxidase. Biochem J 1997; 327: 283-9.
44. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 1998; 16: 387-98.
45. Williamson PR, Kagan HM. Reaction pathway of bovine aortic lysyl oxidase. J Biol Chem 1986; 261: 9477-82.
46. Tang C, Klinman JP. The catalytic function of bovine lysyl oxidase in the absence of copper. J Biol Chem 2001; 276: 30575-8.
47. Trivedy C, Meghji S, Warnakulasuriya KA, Johnson NW, Harris M. Copper stimulates human oral fibroblasts in vitro: a role in the pathogenesis of oral submucous fibrosis. J Oral Pathol of Med 2001; 30: 465-70.
48. Trivedy CR, Warnakulasuriya KA, Peters TJ, Senkus R, Hazarey VK, Johnson NW. Raised tissue copper levels in oral submucous fibrosis. J Oral Pathol Med 2000; 29: 241-8.
49. DiSilvestro RA, Harris ED. Evaluation of (+)-catechin action on lysyl oxidase activity in aortic tissue. Biochem Pharmacol 1983; 32: 343-6.
50. Cetta G, Gerzeli G, Quartieri A, et al. Protective effect of flavonoids on the collagen of lathyritic rats. Experientia 1971; 27: 1046-8.
51. Akagawa M, Suyama K. Amine oxidase-like activity of polyphenols. Mechanism and properties. Eur J of Biochem 2001; 268: 1953-63.
52. Madhan B, Dhathathreyan A, Subramanian V, et al. Investigations on geometrical features in induced ordering of collagen by small molecules. Proc Indian Acad Sci (Chem Sci) 2003; 115: 751-66.
53. Feres-Filho EJ, Choi YJ, Han X, Takala TE, Trackman PC. Pre- and post-translational regulation of lysyl oxidase by transforming growth factor-β 1 in osteoblastic MC3T3-E1 cells. J Biol Chem 1995; 270: 30797-803.
54. Hong HH, Uzel MI, Duan C, Sheff MC, Trackman PC. Regulation of lysyl oxidase, collagen, and connective tissue growth factor by TGF-beta1 and detection in human gingiva. Lab Invest 1999; 79: 1655-67.
55. Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
56. Oku N, Matsukawa M, Yamakawa S, et al. Inhibitory effect of green tea polyphenols on membrane-type 1 matrix metalloproteinase, MT1-MMP. Biol Pharm Bull 2003; 26: 1235-8.
57. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-22.
58. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21: 2245-52.
59. Liotta LA, Stetler-Stevenson W. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Natl Cancer Inst 1989; 81: 556-7.
60. Shieh DH, Chiang LC, Shieh TY. Augmented mRNA expression of tissue inhibitor of metalloproteinase-1 in buccal mucosal fibroblasts by arecoline and safrole as a possible pathogenesis for oral submucous fibrosis. Oral Oncol 2003; 39: 728-35.
61. Chang YC, Yang SF, Tai KW, Chou MY, Hsieh YS. Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol 2002; 38: 195-200.
62. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
63. Ellis V, Wun TC, Behrendt N, Ronne E, Dano K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 1990; 265: 9904-8.
64. HE CS, Wilhelm SM, Pentland AP, et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632-6.
65. Yang SF, Hsieh YS, Tsai CH, Chou MY, Chang YC. The upregulation of type I plasminogen activator inhibitor in oral submucous fibrosis. Oral Oncol 2003; 39: 367-72.
66. Tietze L, Eibrecht A, Schauerte C, et al. Modulation of pro- and antifibrinolytic properties of human peritoneal mesothelial cells by transforming growth factor beta1 (TGF-beta1), tumor necrosis factor alpha (TNF-alpha) and interleukin 1beta (IL-1beta). Thromb Haemostasis 1998; 79: 362-70.